Using two murine BC models (EMT6 and 4T1), treatment with a dual C3aR/C5aR1 agonist significantly slowed mammary tumor development and progression, suggesting that complement activation peptides can influence the anti-tumor response in different ways [104]. This evidence concerns the gene C5AR1 and breast cancer.